Le Lézard
Classified in: Health, Science and technology
Subject: TDS

Intec Pharma to Participate in the Oppenheimer Specialty Pharma Summit



JERUSALEM, October 6, 2017 /PRNewswire/ --

Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced that management will participate in the Oppenheimer Specialty Pharma Summit to be held October 11, 2017 at the Sofitel Hotel in New York City.

Date:  Wednesday, October 11, 2017

Venue: Sofitel New York Hotel

Format:  One-on-One Meetings with Investors

Presenter: Jeffrey A. Meckler, Chief Executive Officer of Intec Pharma

The investor presentation will be posted to the Events section of the Company's website at http://www.intecpharma.com.  

About Intec Pharma Ltd. 

Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company's Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. The Company's product pipeline includes two product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, or AP-CD/LD, which is being developed for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients, and AP-CBD/THC, an Accordion Pill with the two primary cannabinoids contained in Cannabis sativa, cannabidiol (CBD) and tetrahydrocannabinol (THC), which is being developed for various indications including low back neuropathic pain and fibromyalgia.

Contacts:
Jeffrey A. Meckler
Chief Executive Officer
Intec Pharma Ltd.
+1-646-374-8050
jeffrey@intecpharma.com  

SOURCE Intec Pharma Ltd.


These press releases may also interest you

at 13:36
Experts in pediatric heart disease from multiple centers worldwide are sharing their findings at a large national conference sponsored by the Cardiac Center at Children's Hospital of Philadelphia (CHOP). Cardiology 2018, the 21th Annual Update on...

at 12:46
Terumo BCT announced today that it will be the exclusive distributor for Stafa Cellular Therapy (StafaCT), a U.S.-based software developer. StafaCT software supports healthcare facilities and cell labs as they manage each phase of the cellular...

at 12:15
JUUL Labs, Inc. today announced results from a preliminary study on the temperature regulation and harmful and potentially harmful constituents (HPHCs) of JUUL's Virginia Tobacco 5% nicotine-e-liquid filled pod. The findings, "Characterization of...

at 10:00
A new study reveals that most adults hold beliefs about the harms from nicotine that are opposite from what scientists have concluded. The findings, presented at the Society for Research on Nicotine and Tobacco 24th Annual Meeting in Baltimore,...

at 07:34
Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, announces that it has filed a class action against MiMedx Group, Inc. ("MiMedx" or the "Company") and certain of its officers for violations of...

at 03:00
SAN RAFAEL, Calif., Feb. 24, 2018 /PRNewswire-PRWeb/ -- Michael Moskowitz, MD, MPH and Randy Perretta of Anandamedicine, Bill Heriot of Liposome Formulations Inc, George Bianchini of Medi-Cone and Leonard Leinow of Synergy Wellness have joined to...




News published on 6 october 2017 at 07:00 and distributed by: